POSA148 Cost Effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

Autor: Mouallif, S, Thomas, K, Adlard, NE, Cooney, P, Blanchette, F, Patel, BP, Baharnoori, M, Bhan, V, Clift, F, Grima, D
Zdroj: In Value in Health January 2022 25(1) Supplement:S63-S63
Databáze: ScienceDirect
Externí odkaz: